A patent is an exclusive right granted by the State to an inventor for a limited period (20 years) in exchange for public disclosure of the invention. It gives the patentee the right to exclude others from making, using, selling, or importing the patented invention. The Patents Act, 1970 is India's principal statute governing patents.
Why: Patents embody the incentive-disclosure bargain: the State grants a temporary monopoly so the inventor discloses how the invention works (in the complete specification). After expiry, the invention enters the public domain, advancing collective knowledge.
Legal Framework
| Statute/Provision | Subject |
|---|---|
| Patents Act, 1970 | Principal Act governing patents in India |
| S.2(1)(j) | Definition of "invention" |
| S.2(1)(ja) | "Inventive step" |
| S.2(1)(l) | "New invention" (novelty) |
| S.2(1)(ac) | "Capable of industrial application" |
| S.48 | Rights of patentee |
| S.53 | Term of patent (20 years) |
| TRIPS Art. 27-34 | International minimum standards |
Concept of Patent
Definition of "invention" (S.2(1)(j))
"Invention" means a new product or process involving an inventive step and capable of industrial application.
Three requirements for patentability
| Requirement | Section | Test |
|---|---|---|
| Novelty | S.2(1)(l) | Invention not anticipated by prior publication or prior use anywhere in the world before the priority date |
| Inventive step | S.2(1)(ja) | Feature that involves technical advance compared to existing knowledge OR has economic significance OR both, and that makes the invention non-obvious to a person skilled in the art |
| Industrial application | S.2(1)(ac) | Invention is capable of being made or used in an industry |
Nature of a patent
| Feature | Explanation |
|---|---|
| Statutory grant | Created only by Act of the Controller/Patent Office |
| Territorial | Indian patent protects only within India |
| Time-limited | 20 years from filing date (S.53) |
| Negative right | Right to exclude others; not affirmative right to practice |
| Personal property | Assignable, licensable, mortgageable (S.68-70) |
| Subject to State power | Government can acquire (S.100-102), impose compulsory licence (S.84) |
Historical Overview of Patent Law in India
| Year | Development |
|---|---|
| 1856 | Act VI of 1856: India's first patent legislation (based on UK 1852 Act); introduced "exclusive privileges" for inventions |
| 1859 | Act XV of 1859: renamed "letters patent for inventions"; established procedure |
| 1872 | Patents and Designs Protection Act, 1872 |
| 1883 | Protection of Inventions Act, 1883 |
| 1888 | Inventions and Designs Act, 1888: consolidated patent and design law |
| 1911 | Indian Patents and Designs Act, 1911: comprehensive statute modelled on UK Act; governed India until 1972 |
| 1949 | Justice Bakshi Tek Chand Committee: recommended comprehensive patent reform |
| 1959 | Justice N. Rajagopala Ayyangar Committee: recommended process patents only for food/drugs, compulsory licensing, shorter terms |
| 1970 | Patents Act, 1970: enacted based on Ayyangar recommendations; revolutionary features |
| 1972 | Patents Act, 1970 came into force (20 April 1972) |
| 1999 | Patents (Amendment) Act: mailbox system + EMRs (TRIPS compliance phase 1) |
| 2002 | Patents (Amendment) Act: 20-year term, international exhaustion, CL conditions (phase 2) |
| 2005 | Patents (Amendment) Act: product patents for all fields including pharmaceuticals; S.3(d); pre-grant opposition strengthened (phase 3: full TRIPS compliance) |
Salient Features of the Patents Act, 1970
| Feature | Detail |
|---|---|
| Product + process patents | Available in all fields of technology (post-2005) |
| 20-year term | From date of filing (S.53); no extension |
| Working requirement | Patent must be worked in India; non-working triggers CL (S.83-84) |
| Compulsory licensing | S.84 (after 3 years), S.92 (national emergency) |
| Pre-grant opposition | S.25(1): any person may oppose before grant |
| Post-grant opposition | S.25(2): any interested person may oppose after grant |
| S.3 exclusions | 16 categories of non-patentable subject matter |
| S.3(d) | Anti-evergreening: bars new forms without enhanced efficacy |
| Government use | S.100-102: government may use patented invention for public purpose |
| Secrecy directions | S.35: Controller may restrict publication for defence |
| Disclosure obligation | S.8: applicant must disclose corresponding foreign applications |
| Specification | S.10: complete specification must disclose invention sufficiently for person skilled in art |
Kinds of patents
| Type | Description | Indian law |
|---|---|---|
| Product patent | Protects the product itself (any form, method of manufacture) | Available for all fields post-2005 |
| Process patent | Protects specific method of manufacture | Always available under 1970 Act |
| Patent of addition | Patent for improvement/modification of already patented invention | S.54-56; term coextensive with main patent |
| Convention patent | Filed claiming priority from foreign application | S.135; 12-month priority (Paris Convention) |
| National phase (PCT) | International application entering India | S.7(1A); via PCT route |
Illustrations
-
Product patent vs process patent (the critical difference): PharmaCo patents Drug X (the molecule itself) as a PRODUCT patent. GenericCo discovers a completely different chemical route to make the same molecule. Can GenericCo sell Drug X? NO — because the product patent covers the molecule regardless of HOW it's made. Any method of making Drug X infringes.
Now imagine PharmaCo only has a PROCESS patent (for Method A to make Drug X). GenericCo uses Method B (different route, same end product). Can GenericCo sell Drug X? YES — because only Method A is patented. The product itself is unprotected. This is exactly why pre-2005 India (process patents only for pharma) enabled the generics industry.
-
Patent of addition (real scenario): Biocon patents a biologic drug (Drug Y) in 2024 (main patent expires 2044). In 2027, Biocon discovers that adding a specific stabiliser extends Drug Y's shelf-life from 6 months to 2 years. Biocon files a patent of addition (S.54) for this improvement. Key advantage: the patent of addition expires WITH the main patent (2044), not 20 years from 2027. No separate renewal fees. Limitation: it can only cover improvements TO the main patent, not independent inventions.
-
Why Ayyangar Committee shaped India differently: In 1959, India was poor. MNCs held product patents on essential medicines but didn't manufacture in India (imported at high prices). Indian companies couldn't make cheaper versions because the PRODUCT was patented. Ayyangar recommended: "Only grant process patents for food and drugs." Result: Indian companies could reverse-engineer the same drug using different manufacturing routes. This made India the "pharmacy of the developing world" — until TRIPS forced product patents in 2005.
Recall Check
- What are the three requirements for an invention to be patentable under Indian law?
- What was the key recommendation of the Ayyangar Committee that shaped the 1970 Act?
- How did the 2005 Amendment change Indian patent law regarding pharmaceuticals?
Key Cases
Biswanath Prasad v. Hindustan Metal Industries (1979) Biswanath-Prasad-v-Hindustan-Metal-Industries-1979 Issue: Whether a "process" for making brass pots with a particular finish involved an inventive step. Rule: An invention must involve an "inventive step" (now S.2(1)(ja)); the improvement must not be obvious to a person skilled in the art. Workshop improvement without inventive ingenuity does not qualify. Held: Patent revoked. The alleged invention was merely a workshop improvement obvious to skilled artisans; no inventive step was demonstrated. Established that routine trade variation without technical advance is not patentable.
Dimminaco AG v. Controller of Patents (2002) Dimminaco-AG-v-Controller-of-Patents-2002 Issue: Whether a process for producing a living vaccine (containing live organisms) was patentable. Rule: A "manufacture" includes any new and useful art; a process producing a vendible product (even if the product contains living material) is a patentable process. Held: Patent granted. The process of preparing a vaccine involving living organisms is patentable as a "process" producing a commercially useful end product. Expanded scope of process patents in India.
Distinctions
| Parameter | Pre-2005 Indian Patent Law | Post-2005 Indian Patent Law |
|---|---|---|
| Pharmaceutical patents | Process patents only | Product + process patents |
| Term | 14 years (5-7 for food/drugs) | 20 years for all |
| Evergreening | Not an issue (no product patents) | Controlled by S.3(d) |
| TRIPS compliance | Non-compliant | Fully compliant |
| Opposition | Only post-grant | Pre-grant (S.25(1)) + post-grant (S.25(2)) |
| Compulsory licensing | Automatic licensing for food/drugs (S.87 old) | S.84: application-based after 3 years |
Flashcards
Q: What is the definition of "invention" under S.2(1)(j) of the Patents Act? A: A new product or process involving an inventive step and capable of industrial application.
Q: What is the term of a patent in India? A: 20 years from the date of filing the application (S.53).
Q: What committee's recommendations formed the basis of the Patents Act, 1970? A: Justice N. Rajagopala Ayyangar Committee (1959).
Q: When did the Patents Act, 1970 come into force? A: 20 April 1972.
Q: What was the key change introduced by the 2005 Amendment? A: Introduction of product patents for all fields of technology including pharmaceuticals and agrochemicals, achieving full TRIPS compliance.
Q: What is the difference between a product patent and a process patent? A: Product patent protects the product itself (regardless of manufacturing method); process patent protects only the specific method of making the product (same product made by different process does not infringe).
Q: What is a patent of addition (S.54)? A: A patent granted for an improvement or modification of an invention already patented; its term is coextensive with the main patent and no separate renewal fees are payable.
Exam Scenario
In 1998, PharmaCo discovered Drug A (a cancer treatment) and obtained only a process patent under the then-prevailing law. In 2006, GenericCo manufactures Drug A using a different process. PharmaCo now seeks to prevent GenericCo.
Advise: (a) Whether PharmaCo's pre-2005 process patent can prevent GenericCo from using a different process to make the same product. (b) Whether PharmaCo could have obtained a product patent in 2005 under the transitional provisions. (c) The significance of the 2005 Amendment for pharmaceutical patent holders. (d) Refer to the distinction between product and process patents in Biswanath Prasad v. Hindustan Metal Industries.